Close

Bristol-Myers Squibb expands biologics manufacturing agreement with Lonza

News
Typography

Bristol-Myers Squibb (BMS) has expanded its existing biologics manufacturing agreement with Switzerland-based Lonza.

The contract is expanded for the production of commercial quantities of a second BMS biologic medicine at Lonza's mammalian manufacturing facility in Portsmouth, New Hampshire.

Terms of the transaction were not disclosed.

Bristol-Myers Squibb global manufacturing and supply president Lou Schmukler said: "Our expanded relationship with Lonza is an important example of our global manufacturing strategy to meet anticipated demand for our commercial biologics portfolio, and prepare to bring our late-stage clinical assets to patients by supplementing our in-house manufacturing capabilities."

Both companies partnered in 2003 to produce commercial supplies of a biologics medicine marketed by BMS across the globe.

According to BMS, the biologic medicines that treat serious diseases are an integral part of its specialty care portfolio and R&D pipeline. Lonza also manufactures clinical supplies of an investigational biologics medicine for BMS.

Lonza pharma and biotech segment chief operating officer (COO) Marc Funk said: "We are pleased to extend our relationship with Bristol-Myers Squibb for the commercial production of their innovative drug substance.

"This reinforces Lonza's mission to support life-saving medicines by being a reliable supplier of drug substances for our customers with high-quality commercial GMP manufacturing services delivered to the market."

Lonza's additional clinical-to-commercial mammalian production facilities are in Tuas in Singapore, Porrino in Spain and Slough in the UK, as well as its Portsmouth facility.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok